Products Bacillus Clausii
Bacillus Clausii Phase 3 Completed 📈 Rising About Bacillus Clausii Bacillus Clausii is a phase 3 stage product being developed by Sanofi for Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00457353. Target conditions include Gastroenteritis.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT00457353 Phase 3 Completed Mar 1, 2007 — Gastroenteritis NCT00424905 Approved Completed Dec 1, 2006 — Gastrointestinal Diseases
Product Company Stage Hype Score Placebo + HIL-214 HilleVax Phase 1 HIL-214 + Placebo HilleVax Phase 2/3 HIL-214 HilleVax Phase 2 HIL-214 + Placebo HilleVax Phase 2/3 Benralizumab + Placebo AstraZeneca Phase 2/3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 Rotavirus Vaccine Merck Pre-clinical Rotavirus Vaccine, Live, Oral, Pentavalent Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 Prulifloxacin + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 prulifloxacin Merck Phase 3 montelukast Merck Pre-clinical Bacillus clausii + Oral Rehydration Therapy Sanofi Approved VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet Vaxart Phase 1 VXA-G1.1-NN Oral Vaccine Vaxart Phase 1 RHB-102 + Placebo Oral Tablet RedHill Biopharma Phase 3
Other Products from Sanofi